文献速递胸部肿瘤

晚期非小细胞肺癌的抗肿瘤治疗:治疗、生存与花费(2000年至2011年)

Antineoplastic Treatment of Advanced-Stage Non-Small-Cell Lung Cancer: Treatment, Survival, and Spending (2000 to 2011).
PubMed 文献 · J Clin Oncol · 2017-01-03

该研究利用SEER-Medicare数据纳入2000年至2011年间新诊断并接受抗肿瘤药物治疗的晚期非小细胞肺癌老年患者22163例,分析各药物使用比例、治疗天数、生存与诊断后12个月内花费的变化。结果显示培美曲塞、厄洛替尼和贝伐珠单抗使用快速增加而紫杉醇、吉西他滨和长春瑞滨下降,中位生存增益1.5个月,住院花费下降而门诊花费增加23%。作者认为需要更精确的结局信息以支持基于价值的治疗决策。

要点

  • 研究期间培美曲塞(39.2%)、厄洛替尼(20.3%)和贝伐珠单抗(18.9%)使用快速增加。
  • 紫杉醇(38.7%)、吉西他滨(17.0%)和长春瑞滨(5.7%)使用下降,所有P < .05。
  • 接受贝伐珠单抗、厄洛替尼或培美曲塞者平均治疗时间约146天,未接受者约75天。

核心结论

  • 晚期非小细胞肺癌治疗发生显著变化,伴随生存 modest 增益和Medicare总花费变化,需要更精确的结局信息以支持基于价值的治疗决策。

研究设计与样本

  • 利用SEER-Medicare数据,纳入2000年至2011年间新诊断并接受抗肿瘤药物治疗的晚期非小细胞肺癌老年患者22163例,评估调整后各药物使用比例、治疗天数、生存和诊断后12个月内花费。

主要发现

  • 12年研究期间,培美曲塞使用39.2%、厄洛替尼20.3%、贝伐珠单抗18.9%快速增加,紫杉醇38.7%、吉西他滨17.0%、长春瑞滨5.7%下降(所有P < .05)。
  • 平均总治疗天数增加5天(从103天至108天)。
  • 接受贝伐珠单抗、厄洛替尼或培美曲塞者平均治疗时间最长,约146天,未接受这些药物者约75天。
  • 整个研究期间约44%患者在生命最后30天内接受抗肿瘤药物治疗。
  • 急性住院花费下降(从29376美元至23731美元),门诊花费增加23%(从37931美元至46642美元),中位生存增益1.5个月。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Multiple agents for advanced non-small-cell lung cancer (NSCLC) have been approved in the past decade, but little is known about their use and associated spending and survival. Methods We used SEER-Medicare data for elderly patients with a new diagnosis of advanced-stage NSCLC and were treated with antineoplastic agents between 2000 and 2011 (N = 22,163). We estimated the adjusted percentage of patients who received each agent, days while on treatment, survival, and spending in the 12 months after diagnosis. Results During the 12-year study period, a marked shift in treatment occurred along with a rapid adoption of pemetrexed (39.2%), erlotinib (20.3%), and bevacizumab (18.9%) and a decline in paclitaxel (38.7%), gemcitabine (17.0%), and vinorelbine (5.7%; all P < .05). The average total days on therapy increased by 5 days (from 103 to 108 days). Patients who received bevacizumab, erlotinib, or pemetrexed had the longest treatment durations on average (approximately 146 days v 75 days for those who did not receive these agents). Approximately 44% of patients received antineoplastic agents in the last 30 days of life throughout the study period. Acute inpatient spending declined (from $29,376 to $23,731), whereas outpatient spending increased 23% (from $37,931 to $46,642). Median survival gains of 1.5 months were observed. Conclusion Considerable shifts in the treatment of advanced-stage NSCLC occurred along with modest gains in survival and total Medicare spending. More precise outcome information is needed to inform value-based treatment decisions for advanced-stage NSCLC.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Bradley CJ, Yabroff KR, Mariotto AB, et al. Antineoplastic Treatment of Advanced-Stage Non-Small-Cell Lung Cancer: Treatment, Survival, and Spending (2000 to 2011). J Clin Oncol. 2017. PMID: 28045621. doi:10.1200/JCO.2016.69.4166

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。